文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急性呼吸窘迫综合征中呼吸驱动异质性与全身炎症及血管通透性相关

Respiratory drive heterogeneity associated with systemic inflammation and vascular permeability in acute respiratory distress syndrome.
PubMed 文献 · Crit Care · 2024-04-23
一句话结论在ARDS患者中,全身炎症与血管通透性标志物独立于酸碱、氧合、呼吸力学和镇静深度与更高呼吸驱动相关,中度驱动者死亡风险最低。

本研究纳入多中心EPVent-2试验中有基线数据和血浆标志物的ARDS患者124例,排除接受神经肌肉阻滞者,以PES0.1(吸气努力最初0.1秒内食管压变化)测量呼吸驱动,同期检测血浆血管生成素-2、白介素-6、白介素-8并评估60天临床结局。结果显示54.8%的患者可检测到呼吸驱动(PES0.1范围0-5.1 cm H2O);血管生成素-2和白介素-8(而非白介素-6)独立于酸碱状态、氧合、呼吸力学和镇静深度与呼吸驱动相关。镇静深度在未调整模型或调整力学与化学感受器输入后与PES0.1无显著相关,但加入上述任一炎症标志物后,较浅镇静与更高PES0.1显著相关。与低驱动或高驱动相比,中度驱动(PES0.1 0.5-2.9 cm H2O)死亡风险更低(p=0.049)。作者认为呼吸驱动对镇静深度反应的异质性可能部分由炎症和血管通透性差异解释。

要点

  • 124例ARDS患者中54.8%可检测到呼吸驱动,PES0.1范围为0-5.1 cm H2O。
  • 血管生成素-2和白介素-8(而非白介素-6)独立于酸碱、氧合、呼吸力学和镇静深度与呼吸驱动相关。
  • 镇静深度在未调整或调整力学与化学感受器输入后与PES0.1无显著相关;加入血管生成素-2、白介素-6或白介素-8后,较浅镇静与更高PES0.1显著相关。
  • 与低驱动相比,中度驱动(PES0.1 0.5-2.9 cm H2O)死亡风险更低(HR 1.58,95%CI 0.82-3.05);与高驱动相比亦更低(HR 2.63,95%CI 1.21-5.70)(p=0.049)。

适用人群与场景

  • 纳入多中心EPVent-2试验中有必需数据和血浆标志物的ARDS患者。
  • 排除接受神经肌肉阻滞的患者。

诊断标准与关键阈值

  • 呼吸驱动以PES0.1衡量,即吸气努力最初0.1秒内食管压的变化。
  • 驱动分层:低驱动、中度驱动(PES0.1 0.5-2.9 cm H2O)、高驱动。

研究设计与关键结果

  • 研究类型:基于多中心EPVent-2试验数据的分析;样本量124例;排除神经肌肉阻滞者。
  • 54.8%的患者可检测到呼吸驱动,PES0.1范围为0-5.1 cm H2O。
  • 血管生成素-2和白介素-8(而非白介素-6)独立于酸碱状态、氧合、呼吸力学和镇静深度与呼吸驱动相关。
  • 镇静深度在未调整模型或调整力学与化学感受器输入后与PES0.1无显著相关;加入血管生成素-2、白介素-6或白介素-8后,较浅镇静与更高PES0.1显著相关。
  • 与中度驱动(PES0.1 0.5-2.9 cm H2O)相比,低驱动死亡风险HR 1.58(95%CI 0.82-3.05),高驱动死亡风险HR 2.63(95%CI 1.21-5.70)(p=0.049)。

证据类型、等级与局限

  • 证据类型:基于多中心随机对照试验EPVent-2的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,呼吸驱动对镇静深度反应的异质性可能部分由炎症和血管通透性差异解释。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In acute respiratory distress syndrome (ARDS), respiratory drive often differs among patients with similar clinical characteristics. Readily observable factors like acid-base state, oxygenation, mechanics, and sedation depth do not fully explain drive heterogeneity. This study evaluated the relationship of systemic inflammation and vascular permeability markers with respiratory drive and clinical outcomes in ARDS.

METHODS: ARDS patients enrolled in the multicenter EPVent-2 trial with requisite data and plasma biomarkers were included. Neuromuscular blockade recipients were excluded. Respiratory drive was measured as PES0.1, the change in esophageal pressure during the first 0.1 s of inspiratory effort. Plasma angiopoietin-2, interleukin-6, and interleukin-8 were measured concomitantly, and 60-day clinical outcomes evaluated.

RESULTS: 54.8% of 124 included patients had detectable respiratory drive (PES0.1 range of 0-5.1 cm H2O). Angiopoietin-2 and interleukin-8, but not interleukin-6, were associated with respiratory drive independently of acid-base, oxygenation, respiratory mechanics, and sedation depth. Sedation depth was not significantly associated with PES0.1 in an unadjusted model, or after adjusting for mechanics and chemoreceptor input. However, upon adding angiopoietin-2, interleukin-6, or interleukin-8 to models, lighter sedation was significantly associated with higher PES0.1. Risk of death was less with moderate drive (PES0.1 of 0.5-2.9 cm H2O) compared to either lower drive (hazard ratio 1.58, 95% CI 0.82-3.05) or higher drive (2.63, 95% CI 1.21-5.70) (p = 0.049).

CONCLUSIONS: Among patients with ARDS, systemic inflammatory and vascular permeability markers were independently associated with higher respiratory drive. The heterogeneous response of respiratory drive to varying sedation depth may be explained in part by differences in inflammation and vascular permeability.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Baedorf-Kassis E, Murn M, Dzierba AL, et al. Respiratory drive heterogeneity associated with systemic inflammation and vascular permeability in acute respiratory distress syndrome. Crit Care. 2024. PMID: 38654391. doi:10.1186/s13054-024-04920-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。